mpMRI demonstrates superior specificity compared to Micro-US for clinically significant prostate cancer detectionMultiparametric MRI Shows Better Specificity for Prostate Cancer Screening

Prostate cancer and prostatic diseases Published October 5, 2026 Study authors: Garcia-Becerra Carlos A, Arias-Gallardo Maria I, Juarez-Garcia Jesus E, Soltero-Molinar Veronica, El… PubMed ↗ DOI ↗ Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that mpMRI provides significantly higher specificity than Micro-US for detecting clinically significant prostate cancer.

This meta-analysis evaluated the diagnostic accuracy of Micro-ultrasound (Micro-US) compared to multiparametric-MRI (mpMRI) for detecting clinically significant prostate cancer (csPCa) in a population of 2626 patients. The study focused on sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) as primary and secondary outcomes.

The analysis found that Micro-US sensitivity was 0.87 (95% CI: 0.80-0.92) and mpMRI sensitivity was 0.88 (95% CI: 0.81-0.93). The difference in sensitivity between the two modalities was not significant (P = 0.72). However, mpMRI showed significantly higher specificity (0.30; 95% CI: 0.18-0.46) compared to Micro-US (0.25; 95% CI: 0.17-0.36) with a p-value of 0.003. Reported PPV ranged from 0.41 to 0.46, and NPV ranged from 0.72 to 0.80.

Authors noted the need for more high-quality prospective studies to confirm these findings. Clinically, while Micro-US offers comparable sensitivity to mpMRI for csPCa screening, mpMRI is the more specific modality. These results should be interpreted with caution until more prospective data are available.

How this fits prior evidence

This meta-analysis addresses a gap in comparing imaging modalities for prostate cancer detection. While prior coverage noted that PSMA PET/CT shows 95% specificity and 95% NPV for detecting lymph node invasion, this study specifically compares Micro-US and mpMRI for clinically significant prostate cancer. It confirms that mpMRI has superior specificity (0.30) compared to Micro-US (0.25) with a p-value of 0.003, while both show comparable sensitivity.

A large review of data from 2,626 patients looked at how well two different imaging methods find clinically significant prostate cancer. The two methods compared were micro-ultrasound (Micro-US) and multiparametric MRI (mpMRI).

The results showed that both micro-ultrasound and mpMRI have very similar sensitivity, meaning both are effective at detecting the presence of cancer. However, the study found a significant difference in specificity. Multiparametric MRI was found to be more specific than micro-ultrasound. This means MRI is more precise at correctly identifying cases where no significant cancer is present.

Because this was a meta-analysis of existing data, the findings are useful for understanding current tools but require more high-quality prospective studies to be fully confirmed. While micro-ultrasound is a comparable tool for detecting cancer, mpMRI provides better specificity. Patients should talk to their doctors to decide which imaging method is best for their specific care plan.

What this means for you:

Both methods show similar sensitivity, but mpMRI is more specific at identifying significant prostate cancer.

Common questions

How do micro-ultrasound and MRI compare for finding prostate cancer?

Both micro-ultrasound and multiparametric MRI (mpMRI) show similar sensitivity for finding clinically significant prostate cancer. In a study of 2,626 patients, the sensitivity for micro-ultrasound was 0.87, while the sensitivity for mpMRI was 0.88. Because these numbers are so close, both methods are considered comparable for detecting the presence of cancer.

What is the difference in specificity between the two methods?

While both methods find cancer well, mpMRI is more specific. The study found a significant difference in specificity favoring mpMRI. Micro-ultrasound had a specificity of 0.25, while mpMRI had a specificity of 0.30. This means mpMRI is more accurate at identifying cases that do not have significant cancer.

Is one method better than the other for my diagnosis?

The study shows that mpMRI has superior specificity compared to micro-ultrasound, though both have similar sensitivity. Because this was a meta-analysis of 2,626 patients, it provides a broad overview of how these tools perform. You should discuss these specific imaging options with your doctor to determine the best approach for your situation.

Study Details

Study typeMeta analysis

Sample sizen = 2,626

EvidenceLevel 1

PublishedOct 2026

PMID41634333

View Original Abstract ↓

BACKGROUND: Prostate cancer (PCa) remains a leading cause of cancer-related mortality in men. While multiparametric MRI (mpMRI) is an established tool for detecting clinically significant PCa (csPCa), it is limited by cost, access, and acquisition time. Micro-ultrasound (Micro-US) offers real-time imaging with potential advantages in accessibility and integration into routine care. This systematic review and meta-analysis (SR/MA) aimed to compare the diagnostic accuracy of Micro-US versus mpMRI in detecting csPCa, based exclusively on prospective evidence. METHODS: A protocol-registered SR/MA (INPLASY202540027) was conducted following PRISMA and PICOTT frameworks. Prospective cohort studies and randomized controlled trials published between 2012 and March 2025 comparing micro-US and mpMRI for csPCa detection, using biopsy or prostatectomy specimens as reference standards, were included. Bivariate random-effects models were used to estimate pooled sensitivity, specificity, and summary ROC curves. Positive/negative predictive values (PPV/NPV) were calculated using pooled prevalence and literature-based prevalence values. Meta-regression assessed modality differences and potential effect modifiers. RESULTS: Eight prospective studies (n = 2626 patients) met the inclusion criteria, 1 randomized controlled trial and 7 prospective cohorts. Micro-US demonstrated a pooled sensitivity of 0.87 (95%CI: 0.80-0.92) and specificity of 0.25 (95% CI: 0.17-0.36), while mpMRI showed a sensitivity of 0.88 (95% CI: 0.81-0.93) and specificity of 0.30 (95% CI: 0.18-0.46). sROC confidence regions overlapped for both modalities. Meta-regression detected no significant difference in sensitivity (P = 0.72) but a significant difference in specificity favoring mpMRI (P = 0.003). PPVs were modest (0.41-0.46), and NPVs were high (0.72-0.80) across prevalence scenarios. CONCLUSION: Micro-US demonstrates sensitivity comparable to mpMRI for csPCa screening before confirmatory biopsy, although mpMRI retains superior specificity. Micro-US may serve as an accessible alternative or complementary modality, but further high-quality prospective studies are needed to strengthen comparative evidence.

mpMRI demonstrates superior specificity compared to Micro-US for clinically significant prostate cancer detectionMultiparametric MRI Shows Better Specificity for Prostate Cancer Screening

How this fits prior evidence

Common questions

Study Details

Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC

Combination therapy shows mixed results for advanced prostate cancer

Clinical research that matters. Delivered to your inbox.

mpMRI demonstrates superior specificity compared to Micro-US for clinically significant prostate cancer detectionMultiparametric MRI Shows Better Specificity for Prostate Cancer Screening

How this fits prior evidence

Common questions

More on Prostate Cancer

Study Details

Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC

Combination therapy shows mixed results for advanced prostate cancer

Clinical research that matters. Delivered to your inbox.

Related in Urology

From Other Specialties